stub Cannabis Sativa Extract PHEC-66 Shows Promise in Treating Melanoma - MyCannabis.com
Connect with us

Health

Cannabis Sativa Extract PHEC-66 Shows Promise in Treating Melanoma

mm
Updated on

By

Melanoma, a highly aggressive form of skin cancer, poses a significant threat to individuals, accounting for over 80% of skin cancer-related fatalities despite representing only 5.5% of diagnoses.

While immune checkpoint inhibitors like anti-programmed cell death antigen-1 (anti-PD1) and anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) have demonstrated potential in melanoma treatment, their usage has been accompanied by significant adverse drug effects, posing challenges for patient adherence. Additionally, these immunotherapeutic agents may contribute to cancer relapse and the development of post-treatment drug resistance, further constraining their effectiveness. The treatment landscape for metastatic melanoma remains constrained, with patients facing a median survival time of merely 6–9 months and a discouraging 3-year overall survival rate below 15%.

The Role of Cannabis Sativa Extracts

Recent studies have explored the potential of Cannabis sativa extracts in addressing various cancers. Cannabinoids, which signal through CB1 and CB2 receptors, have shown promise in influencing the tumor microenvironment. In a recent study, a Cannabis sativa extract named PHEC-66 was investigated for its antiproliferative effects on melanoma cells.

The study utilized various assays, including the MTT assay, colony formation inhibition assay, in vitro cell migration assays, ultra-structural analysis using transmission electron microscopy, and determination of the effect of PHEC-66 treatments in 3D multicellular spheroids. These methods provided a comprehensive evaluation of PHEC-66's impact on melanoma cells.

Key Findings

PHEC-66 exhibited antiproliferative effects against MM418-C1, MM329, and MM96L melanoma cells, marking the first report of such properties for this particular Cannabis sativa extract. The study suggests PHEC-66 as a potential pharmacotherapeutic agent for melanoma treatment.

While these findings are promising, further research is essential to assess the safety, efficacy, and clinical applications of PHEC-66. The study opens doors for future investigations into the potential of this Cannabis sativa extract as a phytocannabinoid with anticancer properties.

Conclusion

The study underscores the potential of PHEC-66, a Cannabis sativa extract, as a promising candidate in the pursuit of effective melanoma treatments. The findings encourage further exploration into the clinical applications of PHEC-66, offering hope for improved outcomes in melanoma management.

Reference

Bachari, A., Nassar, N., Telukutla, S., Zomer, R., Dekiwadia, C., Piva, T. J., & Mantri, N. (2023). In Vitro Antiproliferative Effect of Cannabis Extract PHEC-66 on Melanoma Cell Lines. Cells, 12(20), 2450. https://doi.org/10.3390/cells12202450

 

Related Topics:
mm

Lydia K. (Bsc. RN) is a cannabis writer, which, considering where you’re reading this, makes perfect sense. Currently, she is a regular writer for Mace Media. In the past, she has written for MyBud, RX Leaf & Dine Magazine (Canada), CBDShopy (UK) and Cannavalate & Pharmadiol (Australia). She is best known for writing epic news articles and medical pieces. Occasionally, she deviates from news and science and creates humorous articles. And boy doesn't she love that! She equally enjoys ice cream, as should all right-thinking people.